Aug 2026
TL;DR
Life sciences and healthcare organizations have spent the last decade digitizing everything, electronic health records, lab systems, wearables, clinical trial platforms, claims data. The result should have been a connected, data-rich ecosystem. Instead, most ended up with dozens of systems that each hold a piece of the picture, none of which talk to each other well.
Interoperability, not data volume, is the real constraint on digital health today. Organizations don't lack data, they lack the ability to move it, trust it, and act on it across the systems and partners it needs to travel through.
Every new device, platform, and partner integration adds another data source. On paper, that's progress. In practice, it often means another format to normalize, another consent framework to manage, another vendor-specific API to maintain. Clinical, operational, and research data frequently sit in silos that were never designed to reconcile, an EHR schema doesn't map cleanly to a clinical trial database, and neither maps cleanly to a wearable's raw sensor output.
The consequence is familiar to anyone who has worked inside a health system or life sciences company: care teams re-entering the same information across systems, researchers spending months on data cleaning before analysis even begins, and safety signals that surface later than they should because the relevant data lives in three places under three formats. None of this is a data problem in the traditional sense, it's an architecture and integration problem, and it requires the kind of cloud enablement and systems implementation work most organizations have underinvested in relative to their front-end digital initiatives.
Frameworks like FHIR (Fast Healthcare Interoperability Resources) have made real progress toward a common language for health data exchange, and regulatory pressure, particularly around information blocking and patient data access, has pushed adoption further than pure market incentives would have. But having a standard available and having an organization's systems actually built around it are two different things.
Most large health systems and life sciences companies run a mix of legacy infrastructure, acquired-company systems, and newer cloud platforms, often accumulated through years of M&A and vendor consolidation. Retrofitting interoperability into that environment isn't plug-and-play, it requires a deliberate technology transformation strategy, not a compliance checkbox next to a FHIR API. Organizations that treat interoperability as a strategic capability, rather than a regulatory obligation, tend to be the ones actually capturing value from their data.
There's a common assumption that AI will simply route around messy data, that a large enough model can make sense of fragmented, inconsistent inputs well enough to be useful. In practice, the opposite tends to be true. AI models built for clinical decision support, drug discovery, or population health are only as good as the data pipelines feeding them. Fragmented, poorly normalized data doesn't just slow AI initiatives down, it degrades model performance and introduces risk in a domain where errors have real clinical consequences.
This is where AI/ML and interoperability work have to move together, not sequentially. Building the data foundation and the intelligence layer as a single initiative, rather than bolting AI onto whatever infrastructure already exists, tends to be the difference between a pilot that never scales and a capability that actually changes outcomes. It's a natural extension of the kind of AI/ML and experience engineering work life sciences organizations increasingly need.
Organizations that get this right tend to share a few habits. They treat data architecture as a long-term investment rather than a project tied to a single system migration. They prioritize a small number of high-value data flows- say, connecting trial data to real-world evidence, or linking claims data to care management, rather than attempting an all-at-once enterprise-wide overhaul. And they build governance around data quality and consent early, rather than retrofitting it once a compliance issue forces the question.
None of this is glamorous work. It rarely shows up in a product demo. But it's the layer everything else in digital health, AI-driven diagnostics, remote patient monitoring, decentralized clinical trials, actually depends on.
For most organizations, the fastest path forward isn't a full-scale data platform overhaul. It's identifying the two or three data flows that create the most friction today, between clinical and research systems, between internal data and external partners, between legacy platforms and newer cloud infrastructure and solving those first.
At Saguna Consulting, we work with health and life sciences leaders on exactly this kind of strategy and operations work: building the data foundation that makes AI, analytics, and better patient outcomes actually possible, rather than perpetually aspirational. If interoperability is the wall your digital health initiatives keep hitting, we'd welcome the conversation.
AI models built for clinical decision support or population health are only as good as the pipelines feeding them. Poorly normalized data doesn't just slow things down, it degrades performance where errors carry real clinical consequences.
